Effects of intranasal fluticasone and salmeterol on allergen-induced nasal responses

Allergy: European Journal of Allergy and Clinical Immunology

Volumn 61, Issue 6, 2006, Pages 731-736

  Parameswaran, K ^a   Fanat, A ^a   O'Byrne, P M ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

Allergic rhinitis; Fluticasone; Nasal allergen provocation; Nasal lavage; Nasal potential; Salmeterol

Indexed keywords

ALBUMIN; ALLERGEN; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; FLUTICASONE PROPIONATE; LONG ACTING DRUG; PLACEBO; SALMETEROL;

ABSENCE OF SIDE EFFECTS; ADULT; ALLERGIC RHINITIS; ALLERGY TEST; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG POTENTIATION; ELECTRIC POTENTIAL; EOSINOPHIL COUNT; FEMALE; HUMAN; INFLAMMATION; LAVAGE; LEUKOCYTE DIFFERENTIAL COUNT; MALE; METERED DOSE INHALER; NOSE ALLERGY; NOSE LAVAGE; NOSE OBSTRUCTION; NOSE PROVOCATION TEST; NOSE SECRETION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; SNEEZING; TREATMENT RESPONSE;

ADMINISTRATION, INHALATION; ADRENERGIC BETA-AGONISTS; ADULT; ALBUTEROL; ANDROSTADIENES; ANTI-ALLERGIC AGENTS; ANTI-INFLAMMATORY AGENTS; BRONCHODILATOR AGENTS; CROSS-OVER STUDIES; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MEMBRANE POTENTIALS; NASAL LAVAGE FLUID; NASAL MUCOSA; NASAL OBSTRUCTION; NASAL PROVOCATION TESTS; NEBULIZERS AND VAPORIZERS; RHINITIS, ALLERGIC, SEASONAL;

EID: 33744473790     PISSN: 01054538     EISSN: 13989995     Source Type: Journal    
DOI: 10.1111/j.1398-9995.2005.00906.x     Document Type: Article

References (20)

1. Howarth PH. The cellular basis for allergic rhinitis. Eur J Allergy Clin Immunol 1995 50 : 6 10.
2. Belda J Parameswaran K Keith PK Hargreave FE. Repeatability and validity of cell and fluid-phase measurements in nasal fluid: a comparison of two methods of nasal lavage. Clin Exp Allergy 2001 31 : 1111 1115.
3. Knowles MR Carson JL Collier AM Gatzy JT Boucher RC. Measurements of nasal transepithelial electric potential differences in normal human subjects in vivo. Am Rev Respir Dis 1981 124 : 484 490.
4. Boucher RC Bromberg PA Gatzy JT. Airway transepithelial electric potential in vivo: species and regional differences. J Appl Physiol 1980 48 : 169 176.
5. Suzumura E Takeuchi K. Antigen reduces nasal transepithelial electric potential differences and alters ion transport in allergic rhinitis in vivo. Acta Otolaryngol 1992 112 : 552 558.
6. Wang D Duyck F Smitz J Clement P. Efficacy and onset of action of fluticasone propionate aqueous nasal spray on nasal symptoms, eosinophil count, and mediator release after nasal allergen challenge in patients with seasonal allergic rhinitis. Allergy 1998 53 : 375 382.
7. Proud D Reynolds CJ Lichtenstein LM Kagey-Sobotka A Togias A. Intranasal salmeterol inhibits allergen-induced vascular permeability but not mast cell activation or cellular infiltration. Clin Exp Allergy 1998 28 : 868 875.
8. Kavuru M Melamed J Gross G Laforce C House K Prillaman B et al. Salmeterol and fluticasone propionate combined in a new powder inhalation device for the treatment of asthma: a randomized, double-blind, placebo-controlled trial. J Allergy Clin Immunol 2000 105 : 1108 1116.
9. Pauwels RA Lofdahl CG Postma DS Tattersfield AE O'Byrne P Barnes PJ et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. N Engl J Med 1997 337 : 1405 1411.
10. Pizzichini E Pizzichini MM Efthimiadis A Evans S Morris MM Squillace D et al. Indices of airway inflammation in induced sputum: reproducibility and validity of cell and fluid-phase measurements. Am J Respir Crit Care Med 1996 154 : 308 317.
11. Johnson M. Interactions between corticosteroids and β2-agonists in asthma and chronic obstructive pulmonary disease. Proc Am Thorac Soc 2004 1 : 200 206.
12. Gagliardo R Merendino A Pompeo F Siena L Bellia V Testi R et al. IKKβ phosphorylation is modulated by the combination of glucocorticosteroids and long acting β2-agonists in human bronchial epithelial cells. Am J Respir Crit Care Med 2003 167 : A653.
13. Seeto LJ Johnson M Hendel N Lim S. Effect of dexamethasone and salmeterol on human alveolar macrophage cytokine production in patients with chronic obstructive pulmonary disease (COPD). Am J Respir Crit Care Med 2002 165 : A597.
14. Eickelberg O Roth M Lörx R Bruce V Rüdiger J Johnson M et al. Ligand-independent activation of the glucocorticoid receptor by the β2-adrenergic receptor agonists in primary human lung fibroblasts and vascular smooth muscle cells. J Biol Chem 1999 274 : 1005 1010.
15. Roth M Johnson PR Rudiger JJ King GG Ge Q Burgess JK et al. Interaction between glucocorticoids and beta2 agonists on bronchial airway smooth muscle cells through synchronised cellular signalling. Lancet 2002 26 360 : 1293 1299.
16. Li X Ward C Thien F Bish R Bamford T Bao X et al. An anti-inflammatory effect of salmeterol, a long-acting β2-agonist, assessed in airway biopsies and bronchoalveolar lavage in asthma. Am J Respir Crit Care Med 1999 160 : 1493 1499.
17. Paulsen DF. Respiratory system. In : Paulsen DF, editor. Basic histology, 2nd edn. Englewood Cliffs : Prentice Hall, 1993 : 24654.
18. Myo S Zhu X Myou S Meliton AY Liu J Boetticher E et al. Additive blockade of beta 2-integrin adhesion of eosinophils by salmeterol and fluticasone propionate. Eur Respir J 2004 23 : 511 517.
19. Sartori C Allemann Y Duplain H Lepori M Egli M Lipp E et al. Salmeterol for the prevention of high-altitude pulmonary edema. N Engl J Med 2002 346 : 1631 1636.
20. Coraux C Kileztky C Polette M Hinnrasky J Zahm JM Devillier P et al. Airway epithelial integrity is protected by a long-acting beta2-adrenergic receptor agonist. Am J Respir Cell Mol Biol 2004 30 : 605 612.